---
title: "LifeTech Scientific Flags Interim Loss on Lower Revenue and One-Off Costs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295677243.md"
description: "LifeTech Scientific (HK:1302) warned of a sharp profit drop and potential net loss for H1 2026 due to lower revenue, reduced exchange gains, and one-off costs like aborted acquisition expenses. Despite this, the company maintains its long-term financial health is robust. The unaudited figures are preliminary; formal results are expected by August 2026."
datetime: "2026-08-12T13:38:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295677243.md)
  - [en](https://longbridge.com/en/news/295677243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295677243.md)
generator: "portal-rs"
---

# LifeTech Scientific Flags Interim Loss on Lower Revenue and One-Off Costs

LifeTech Scientific Corporation ( (HK:1302) ) has shared an announcement.

LifeTech Scientific has warned that its unaudited net profit attributable to shareholders for the six months ended 30 June 2026 is expected to fall sharply to about RMB110 million to RMB120 million, from RMB238.5 million a year earlier, mainly due to lower revenue and a significant reduction in net exchange gains. After factoring in non-recurring items such as share-based payment expenses, fair value changes on financial assets and aborted transaction costs tied to a planned acquisition and convertible bond issue, the group now expects to post a net loss of RMB30 million to RMB40 million versus a RMB55.1 million profit in the first half of 2025.

Management stressed that exchange differences and transaction-related expenses are short-term or one-off in nature and do not undermine the group’s long-term operations or financial health, reiterating that its operational and financial position remains robust and its overall prospects positive. The company cautioned shareholders and potential investors that the figures are based on preliminary unaudited management accounts and may change, urging them to await the formal interim results due by the end of August 2026 and to exercise care when trading its shares.

**More about LifeTech Scientific Corporation**

LifeTech Scientific Corporation, incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical technology sector through a group structure. The company focuses on developing and commercializing cardiovascular and other minimally invasive medical devices, serving hospital and clinical customers primarily in China and international markets.

**Average Trading Volume:** 25,860,303

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$6.5B

For an in-depth examination of 1302 stock, go to TipRanks’ Overview page.

### Related Stocks

- [01302.HK](https://longbridge.com/en/quote/01302.HK.md)

## Related News & Research

- [LifeTech Scientific drops proposed Starway Equity acquisition after failing to reach terms](https://longbridge.com/en/news/293201934.md)
- [Towngas Smart Energy declares interim dividend of HKD 0.05 a share](https://longbridge.com/en/news/296077649.md)
- [Morimatsu International schedules board meeting to review interim results and dividend plan](https://longbridge.com/en/news/296076945.md)
- [TG SMART ENERGY  1H26 Net Profit Falls 9% to HKD690 million; Interim DPS HKD0.05](https://longbridge.com/en/news/296079330.md)
- [Time Interconnect Technology schedules board meeting to review interim results](https://longbridge.com/en/news/296076748.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**